518232 A7 ________B7五、發明説明（1 ) ^ 本發明係關於一種漱口劑組合物，特別是由陽.離子抗菌 劑-雙氯苯雙胍己烷組成之組合物。 w〇93/16681揭示的口腔衛生組合物包括由陽離子抗菌 劑，如雙氯苯雙胍己烷和做爲抗牙斑劑之聚乙烯吡咯烷酮 (P V P )組成的漱口劑。 目蓟已發現一種具有特殊酸驗値範圍的兩相雙氯苯雙胍 己烷/PVP漱口劑，會有促進雙氯苯雙胍己烷的效力。 根據本發明第一方面提供一種由兩相組成的漱口劑組合 物：第一相含有雙氯苯雙胍己烷或其口服上可接受之酸加 成鹽和口服上可接受之載劑或賦形劑，而第二相含有pVP 和口服上可接受之載劑或賦形劑：使用前該兩相係分開保 存’一旦混合後，會產生酸鹼値爲6和1 〇之間的單一相。 因爲已發現雙氯苯雙胍己垸的效力會因爲與P V p長期儲 存而降低，所以最好使用前將雙氯苯雙胍己烷和PVP相分開。 雙氣苯雙胍己烷相和P v P相的酸鹼値在混合後會使酸鹼 値成爲6.0至10.0，以6 〇至9 〇較佳，而6 〇至7 〇更佳，如 6.2。 (請先閲讀背面之注意事項具本頁)518232 A7 ________ B7 V. Description of the invention (1) ^ The present invention relates to a mouthwash composition, particularly a composition consisting of anionic antibacterial agent-diclofenac. The oral hygiene composition disclosed in WO 93/16681 includes a mouthwash composed of a cationic antibacterial agent such as dichlorophenanthridine and polyvinylpyrrolidone (P V P) as an anti-plaque agent. Thistle has discovered that a two-phase diclofenac hexane / PVP mouthwash with a special range of acid tests can promote the efficacy of diclofenac. According to a first aspect of the present invention, there is provided a mouthwash composition consisting of two phases: the first phase contains dichlorophenanthridine or an orally acceptable acid addition salt thereof and an orally acceptable carrier or agent The second phase contains pVP and an orally acceptable carrier or excipient: the two phases are stored separately before use. Once mixed, a single phase between 6 and 10 will be produced. . Because it has been found that the effectiveness of diclofenac hexamidine is reduced due to long-term storage with P V p, it is best to separate diclofenac hexane from PVP before use. The acid-base hydrazone of the diphenanthrene hexane phase and the PvP phase after mixing will cause the acid-base hydrazone to be 6.0 to 10.0, more preferably 60 to 90, and more preferably 60 to 70, such as 6.2. (Please read the notes on the back page first)
I 1- -- 1- II 裝· 、-口 線 經濟部中央標隼局員工消費合作社印製 使用可雙氣苯雙胍己烷相和P V p相以相等重量百分比的 量混合較方便。 -雙氣苯雙胍己烷相適宜之最初酸鹼値不大於6，其具有增 加i氣私雙胍己坑長期儲存安定性的優點。雙氣苯雙胍己烷相適宜之最初酸鹼値最好是3〇至6,〇， 以5.0至5.9更佳，例如5.5至5 9。 ____—_ _ 4 _本纸張尺度適用中國國家標準（CNS ) ---—- I 2 3 2 8 1X 5 A7 B7 五、發明説明 經濟部中央標率局員工消費合作社印製 P VP相適宜之最初酸鹼値爲6.0至10.0，以6.0至9.0較 佳，而6.0至8.0更佳。 P V P相最好含有一種口服上可接受的缓衝液或酸鹼値改 良劑，使得在與雙氯笨雙胍己烷相混合後，能獲得預期的 酸驗値。 口服上可接受的緩衝液和酸驗値改良劑的實施例包括一 種鹼，如氫氧化鈉，或一種酸，如醋酸、葡糖酸、酒石 酸、檸檬酸、乳酸或磷酸或其可溶解的鹽。此等可單獨或 以做爲混合物使用。較佳之緩衝液是醋酸鈉。 緩衝液或酸鹼値改良劑應足量存在以提供預期之緩衝效 果，組合物中的量以0.01至10重量％較適宜，而〇1至2% 更佳。 本發明之組合物能裝在容器内，像有兩個槽可分別存放 於各相的瓶子或管子，該容器有可控制配藥和適用於該前 相之附隨物質混合物之配藥噴嘴。此種组合物也能裝在有 兩個由易開封蓋分開之槽形成的小藥囊内，在使用前打破 能使小藥囊内的兩相混合。 該兩相另外也可以裝在個別袞哭由 取U⑴合合内，在混合和使用前能 配製每種相的必需量。 適用於本發明之聚乙晞吡咯烷酮-，其平均分子量爲至少5,〇〇〇’例如在5,刪至⑽』⑻的範園内，最好在5,刪至 )0,000的範圍内。Sigma化學藥品公司 J GAF公司和Sigma 化學藥品公司市售的聚乙烯吡咯烷 σ ^ ’其平均分子量分別 是 10,000，3 0,000 和 40,000。組人舲山 π '、且口物中聚乙烯吡咯烷酮的 -5- 本紙張尺度適财酬家縣（CNS ) A4^"( 210^97^ (請先聞讀背面之洤意事養再本頁 -裝 、1Τ 線 2 32 8 A7 _ B7 " - —— - _ 、發明説明（3 ) 〜- 適S存在量爲至少0.5重量％，以0.5和30%之間較佳，〇 5 和2 5 %之間更佳，而1和丨5 %之間最佳。 組合物中雙氯苯雙胍己烷或其口服上可接受之酸加成鹽 的適宜存在量爲0.005至1〇重量％，以〇 〇1至5%較佳，而 〇.〇1至2%更佳。 通罝的雙氯苯雙胍己烷包括該些在2 〇 t時溶解度至少爲 °；〇〇5% W/V，以及包括二葡糖酸鹽、二甲酸鹽、二醋酸 鹽、二丙酸鹽、二氫碘酸鹽、二氫氯酸鹽、二乳酸鹽、二 硝酸鹽、硫酸鹽和酒石酸鹽。在這些鹽中，以二葡糖酸 鹽、二醋酸鹽和二氫氯酸鹽較佳。 本發明之組合物也可使用含有離子性含氟化合物。適宜 =離子性含氟化合物包括，例如氟鹽，像氟化⑮；和驗金 屬氟#例如氟化鈉；以及單氟嶙酸鹽，像驗金屬單氟轉 紅盤’例如單氟.彻鈉。適宜的離子性含氟化合物係接入 、、且口物内以使其成爲5 〇和2〇〇〇 ρ—之間的氟離子，而以 100和5 00 ppm之間較佳。 本發明之組合物由最好可溶於水或水/乙醇溶液内之界 面活性劑和視情況以濕潤劑做爲載劑成份組成較適宜。 經濟部中央標準局員工消費合作社印製 菘些熟於此藝者明瞭爲了確保雙氣苯雙胍己烷的抗菌效 力不會逐漸降低’所以要選用與口-服上可接受之載劑或賦 形劑相容的成份做爲内交必 馬円合物此外，由於陰離子種類會與 雙氣苯雙胍己烷形成不：έ π、取一& ^ , 、 7成不，合/；L表物，典法產生活化作用，所 以應遠取好避免這歧種顏。「〆 _ 一 、一禋Μ 因此，應孩最好不用陰離子界 面活性劑和陰離子渴潤剞 ' Γ1 "，J 而奴用非離子的配對物，例如 518232 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明（4 ) 非陰離子、陽離子或兩相離子界面活性劑和非離子濕潤 劑。 ”’、 適宜的非離子界面活性劑包括，例如聚乙氧基山梨醇 酉旨，特別是聚乙氧基山梨醇單酯，例如peg(40)、脱水山 梨醇二異硬脂酸酯，和I C I市售商標名爲「Tween」之產 口口 ’ 3衣氧乙和氧化丙烯的縮聚物（P〇l〇xainers)，例如 BASF-Wyandotte市售商標名爲Γ Pluronic」之產品；丙二 知的縮合物：聚乙氧基氫化蓖麻油，例如crem〇ph〇rs ;和 脱水山梨醇脂肪酯。 適宜的兩性界面活性劑包括，例如長鏈咪唑啉衍生物， 像Miranol市售商標名爲「Miranol C2M」之產品；長鏈燒 基二.甲録乙内g旨，例如Albright+Wilson市售商標名爲 「Empigen BB」之產品，以及長鏈烷基醯胺烷基三甲銨乙 内酯，像柯卡醯胺丙基三甲銨乙内酯和其混合物。 適罝的陽離子界面活性劑包括乙基-N -可可基-L -精胺酸 鹽的D，L - 2 - p比p各：fe _ - 5 -幾酸鹽，Ajinomoto公司市售商標 名爲「C A E」之產品。 較佳的界面活性劑包括非離子含氧聚合物（poloxamers；) 和聚乙氧基氫化萬麻油。 已發現如果結合相的酸鹼値在6呈1 0之間，最好在6至8 之間，更能促進這些界面活性劑與雙氣苯雙胍己烷的相容 性。 一 組合物中界面活性劑的存在範圍以0.005至5重量％較 佳，以0.005至1%最佳，而0.01至0.5%更佳。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） (請先閱讀背面之注意事項再本頁) •裝·I 1--1- II Equipment · Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs It is convenient to mix the gas phase of Phenylguanidine and P V p in equal weight percentages. -The suitable initial acid-base ratio of diphenanthrene hexane phase is not greater than 6, which has the advantage of increasing the stability of long-term storage stability of dianthridine. The suitable initial acid-base hydrazone of the diphenanthrene hexane phase is preferably 30 to 6,0, more preferably 5.0 to 5.9, such as 5.5 to 59. ____—_ _ 4 _ This paper size applies to Chinese National Standards (CNS) ------ I 2 3 2 8 1X 5 A7 B7 V. Description of the invention The P VP printed by the Consumer Standards Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs is suitable The initial pH is from 6.0 to 10.0, preferably from 6.0 to 9.0, and more preferably from 6.0 to 8.0. The PVP phase preferably contains an orally acceptable buffer or acid-base rhenium modifier so that the desired acid test can be obtained after mixing with dichlorobenzidine hexane. Examples of orally acceptable buffers and acid test improvers include a base such as sodium hydroxide, or an acid such as acetic acid, gluconic acid, tartaric acid, citric acid, lactic acid or phosphoric acid or a soluble salt thereof. . These can be used alone or as a mixture. A preferred buffer is sodium acetate. Buffers or acid-base-modifying agents should be present in sufficient amounts to provide the desired buffering effect. The amount in the composition is preferably from 0.01 to 10% by weight, and more preferably from 0 to 2%. The composition of the present invention can be contained in a container, such as a bottle or tube having two grooves which can be stored in each phase separately, and the container has a dispensing nozzle which can control the dispensing and the accompanying substance mixture suitable for the previous phase. Such a composition can also be contained in a small sachet formed by two grooves separated by an easy-opening cap, which can be broken before use to mix the two phases in the small sachet. The two phases can also be contained in individual mixing units, and the necessary amount of each phase can be prepared before mixing and use. Polyacetone-pyrrolidone- suitable for the present invention has an average molecular weight of at least 5,000, for example, within the range of 5, ⑽ to ⑽ ⑻, and preferably in the range of 5, to 0,000. The commercially available polyvinylpyrrolidines σ ^ 'by Sigma Chemical Company J GAF Company and Sigma Chemical Company are 10,000, 30,000, and 40,000, respectively. Group of people 舲 山 π ', and polyvinylpyrrolidone in the mouth -5- This paper size is suitable for financial remuneration (CNS) A4 ^ " (210 ^ 97 ^ (Please read the intentions on the back to support This page-installed, 1T line 2 32 8 A7 _ B7 "------_, invention description (3) ~-suitable S is at least 0.5% by weight, preferably between 0.5 and 30%, 〇5 It is more preferably between 25 and 25%, and most preferably between 1 and 5%. The suitable amount of diclofenac hexane or an orally acceptable acid addition salt thereof is 0.005 to 10% by weight. %, More preferably from 0.001 to 5%, and more preferably from 0.001 to 2%. Perchlorbiquat hexane includes those whose solubility is at least ° at 20 t; 0.05% W / V, and include digluconate, diformate, diacetate, dipropionate, dihydroiodate, dihydrochlorate, dilactate, dinitrate, sulfate, and tartrate Among these salts, digluconate, diacetate, and dihydrochloride are preferred. The composition of the present invention can also use ionic fluorine-containing compounds. Suitable = ionic fluorine-containing compounds include, for example, Fluoride salt, Thallium fluoride; and test metal fluorine # such as sodium fluoride; and monofluorosulfonate, such as metal monofluoride to red disk 'such as monofluoro. Sodium. Suitable ionic fluorine-containing compounds are connected, and the mouth So that it becomes a fluoride ion between 50 and 2000p-, preferably between 100 and 5000 ppm. The composition of the present invention is preferably soluble in water or a water / ethanol solution. The surfactant and the humectant as the carrier component are more suitable for the composition. It is printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. Some of the artists know this in order to ensure the antibacterial effect of diphenanthrene. It will gradually decrease, so we must choose ingredients compatible with oral-serving acceptable carriers or excipients as the internal pymidine compound. In addition, due to the type of anion, it will not form with diphenanthrene: έ π, take one & ^,, 70%, and /; L surface, the Codex has an activation effect, so it should be far removed to avoid this ambiguity. "〆_ 一 、 一 禋 Μ Therefore, should It is better not to use anionic surfactants and anionic thirst 剞 'Γ1 ", J and slave non Mate, such as 518232 A7 B7 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (4) Non-anionic, cationic or biphasic ionic surfactants and non-ionic wetting agents. "', Suitable non-ionic Surfactants include, for example, polyethoxy sorbitol, especially polyethoxy sorbitol monoesters, such as peg (40), sorbitan diisostearate, and ICI marketed under the trade name " "Tween" product "Polyoxane and propylene oxide polycondensate (Polloxiners), such as BASF-Wyandotte marketed under the name of Γ Pluronic" products; polycondensation of polyethene: polyethoxylate Hydrogenated castor oils, such as cromophos; and sorbitan fatty esters. Suitable amphoteric surfactants include, for example, long-chain imidazoline derivatives, such as those sold under the brand name "Miranol C2M" by Miranol; long-chain alkyl radicals, such as Albright + Wilson trademark Products named "Empigen BB", as well as long-chain alkylamidoalkyltrimethylammonium lactones, like cocamidopropyltrimethylammonium lactone and mixtures thereof. Suitable cationic surfactants include ethyl-N-cocoyl-L-spermine salt D, L-2-p ratio p each: fe _-5-several acid salts, marketed under the trade name of Ajinomoto Corporation "CAE" products. Preferred surfactants include non-ionic oxygenated polymers (poloxamers;) and polyethoxy hydrogenated sesame oil. It has been found that if the acid-base hydrazone of the binding phase is between 6 and 10, preferably between 6 and 8, the compatibility of these surfactants with diphenanthrene hexane is more promoted. A surfactant is preferably present in the composition in a range of 0.005 to 5% by weight, more preferably 0.005 to 1%, and more preferably 0.01 to 0.5%. This paper size applies to Chinese National Standard (CNS) A4 (210X 297 mm) (Please read the precautions on the back before this page) • Loading ·
、1T 線 518232 A7 B7 五、發明説明（ 經濟部中央標準局員工消費合作社印製 適用於本發明之組合物的適宜濕潤劑包括例如甘油、^ 梨醇、丙二醇或聚乙二醇或是其混合物。組合物中該濕消 劑存在的範圍爲5至7 0重量％，以5至3 0 %較佳，而5 j 2 0%更佳。 如果有需要，組合物也可加入其它物質，例如增甜劑、 增香劑、增色劑、防腐劑和乳化劑。 避罝足PVP相包含一種增甜劑，像苯甲醯亞胺鈉，其係 可以有效地保持與雙氯苯雙胍己烷相分開，因而可以預防 長期儲存時不必.要的雙氣苯雙胍己燒/雙氯苯雙脈己貌複 合物沉澱。由按照規定比例而且以任何方便之次序混合其成份，可 =備根據本發明之组合物，其後若有需要，可將酸驗値 凋整芏規定値。 又鼠冬又胍己烷有關的牙斑。 之：二:：發明另-方面也提供-種如前文定義用於治療 =劑组合物，特別是抗牙斑、、抗牙 或牙周，（包括抗—齒齦炎）治療。 見在参考以下列實施例説明本發明。 實施例1冑氣笨雙胍己烷漱口劑— (讀先閱讀背面之注意事嗔再本頁 —-----1..... 1- - - I 11--· ! — II 1 1— I..... ! 1 !.1T line 518232 A7 B7 V. Description of the invention (Suitable humectants printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs for use in the composition of the present invention include, for example, glycerin, sorbitol, propylene glycol, or polyethylene glycol or mixtures thereof The composition is present in a range of 5 to 70% by weight, more preferably 5 to 30%, and more preferably 5 j 2 0%. If necessary, the composition can also be added with other substances, such as Sweeteners, flavorants, colorants, preservatives and emulsifiers. PVP avoidance phase contains a sweetener, like sodium benzamidine, which can effectively maintain the phase with diclofenac Separate, so that it is not necessary for long-term storage. Desired diphenanthrene hexanoate / dichlorobenzene divehide complex appearance precipitation. By mixing its ingredients according to the prescribed ratio and in any convenient order, it can be prepared according to the present invention The composition, if necessary, can be adjusted for acid testing. The plaques related to winter guanidine and guanidine are also described. Two :: Another aspect of the invention is also provided. In treatment = agent composition, especially anti-plaque, Anti-tooth or periodontal (including anti-gingivitis) treatment. See the following examples to illustrate the present invention. Example 1 Breathing biguanidine hexane mouthwash-(Read the precautions on the back and read the text first) Page —----- 1 ..... 1---I 11-- ·! — II 1 1— I .....! 1!.
、1T 本纸張尺度適％ -8 )A4規格（210X297公釐） 5 2 3 2 8 A7 B7 五、發明説明（6 ) 成份％ w/w 雙氯苯雙胍己烷相 % w/w PVP相 % w/w PVP - 15.000 苯甲Si亞胺納 - 0.104 醋酸鈉 - 1.400 雙氯笨雙胍己烷葡糖酸鹽 0.400 - 甘油 10.000 - 染液 0.100 0.100 乙醇 5.000 8.000 Cremophor RH60* 0.200 0.250 食用油 0.120 0.120 去離子水 84.180 75.026 總計 100.00 100.00 在混合物其酸驗値爲 最初酸驗値 最初酸驗値 6.20 =5.90 -6.30 (讀先閲讀背面之法意事亦再IPr本頁 經濟部中央標準局員工消費合作社印製 * Cremophor RH60是在聚乙氧基鏈上平均含有60個乙氧基 單位的聚乙氧基氫化蓖麻油。 實施例2 雙氯苯雙胍己烷酸鹼値對於以漱口劑塗在羥磷灰 石片上與唾液結合之效果 由本藝中已知，因爲雙氣苯雙胍己烷的效果決定於其與 口腔表面結合的能力，所以雙氯苯雙胍己烷與羥磷灰石結 合是口腔韻齒的一種有效活性指標。 以下的試驗方法能用來測定雙氯苯雙胍己烷與羥磷灰石 在體外的結合程度：- _：__ 本纸張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） A7 發明説明 ， a) 將已知表面積的幾鱗灰石片浸主 收集的人類唾液中一夜。 3 、，生消母.、過濾後 b) 然，以25毫升切子水潤濕該片15秒。 c )接著將每片浸沒在5亳井气私、^、 y-g 升忒舫；谷硬内處理6 0秒，繼而 在60秒期間以25毫升等份去離子水沖洗3次。 d)然後由該片萃取出社人产 千取出、、.°合的雙氯苯雙胍己烷，而且以 Η P L C分析。 爲了分析酸鹼値對於雙氣苯雙胍己烷結合的效果，製備 ㈣於表1和表2的對照溶液和漱口劑。錢利社述方法 刀析產物中雙氣苯雙胍己烷的結合。獲得的結果顯示於表 (請先Μ讀背面之雲事嘎再III'本頁} •裝· 表1 標準％w/w 漱口劑 1 2 3 4 雙氣苯雙胍己烷葡糖酸鹽 0.00 0.03 0.06 0.09 0.1M醋酸鈉緩衝液 至 100.00 至 100.00 至 100.00 至 100.00 酸驗値' 7.0 7.0 7.0 7.0 線_ 經濟部中央標準局員工消費合作社印製 表2 待試驗漱口劑％界/\¥ 漱口劑··- 5 6 7 8 9 10 雙氣苯雙胍己烷葡糖 酸鹽 0.06 0.06 0.06 0.06 0.06 0.06 -10- 本紙張尺度適用中國國家標準（CNS ) A4規格（210><297公釐） 518232 經濟部中央標準局員工消費合作社印製 五、發明説明（8 )、 1T The size of this paper is suitable% -8) A4 size (210X297 mm) 5 2 3 2 8 A7 B7 V. Description of the invention (6) Composition% w / w diclofenac hexane phase% w / w PVP phase % w / w PVP-15.000 Benzosiimine sodium-0.104 Sodium acetate-1.400 Dichlorobenzylguanidine gluconate 0.400-Glycerin 10.000-Dye solution 0.100 0.100 Ethanol 5.000 8.000 Cremophor RH60 * 0.200 0.250 Edible oil 0.120 0.120 Deionized water 84.180 75.026 Total 100.00 100.00 In the mixture, the acidity test is the initial acidity test. The initial acidity test is 6.20 = 5.90 -6.30. Printed * Cremophor RH60 is a polyethoxylated hydrogenated castor oil containing an average of 60 ethoxy units on the polyethoxy chain. Example 2 Dichlorobenzidine hexanoic acid base For the application of a mouthwash to hydroxy The effect of binding saliva on apatite tablets is known in the art, because the effect of diphenanthrene hexane depends on its ability to bind to the surface of the oral cavity, so the combination of diphenanthridine and hydroxyapatite is an oral rhyme An effective job of teeth The following test methods can be used to determine the in vitro binding degree of diclofenac and hydroxyapatite:-_: __ This paper size applies to the Chinese National Standard (CNS) A4 (210X 297 mm) ) A7 invention description, a) Soak a few scale limestone pieces of known surface area into human saliva collected by the host overnight. 3. Remove the mother. After filtering b) Then, moisten the tablet with 25 ml of cut water for 15 seconds. c) Subsequently immerse each piece in a 5 亳 well gas, 、, y-g liter; grain hard internal treatment for 60 seconds, and then rinse 3 times with 25 ml aliquots of deionized water during 60 seconds. d) Then, from the tablet, a thousand and one hundred degrees of dichlorophenformin hexane were extracted, and analyzed by Η PL LC. In order to analyze the effect of acid-base tritium on the binding of diphenanthrene and hexane, control solutions and mouthwashes that were tritium in Tables 1 and 2 were prepared. The method described by Qian Lishe analyzed the binding of diphenanthridine in the product. The results obtained are shown in the table (please read the Yunshiga on the back III, then this page). • Packing · Table 1 Standard% w / w mouthwash 1 2 3 4 Diphenanthrene gluconate 0.00 0.03 0.06 0.09 0.1M sodium acetate buffer solution to 100.00 to 100.00 to 100.00 to 100.00 acid test '7.0 7.0 7.0 7.0 line _ printed by the Consumers' Cooperatives of the Central Standards Bureau of the Ministry of Economy Table 2 Mouthwash to be tested Oral preparations ·· 5 6 7 8 9 10 Diphenanthrene hexane gluconate 0.06 0.06 0.06 0.06 0.06 0.06 -10- This paper size applies to the Chinese National Standard (CNS) A4 specifications (210 > < 297 mm ) 518232 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs V. Invention Description (8)
Cremophor RH60 0.225 0.225 0.225 0.225 0.225 0.225 食用油 0.12 0.12 0.12 0.12 0.12 0.12 乙酸96 6.50 6.50 6.50 6.50 6.50 6.50 藍色染液 0.10 0.10 0.10 0.10 0.10 0.10 甘油 5.00 5.00 5.00 5.00 5.00 5.00 PVP 5.00 5.00 5.00 5.00 5.00 5.00 醋酸鈉 0.70 0.70 0.70 0.70 0.70 0.70 氟化鈉 0.05 0.05 0:05 0.05 0.05 0.05 苯甲醯亞胺鈉 0.052 0.052 0.052 0.052 0.052 0.052 醋酸溶液50% w/w 0.625 痛 細 NaOH 溶液 10.2% w/w 輪 0.073 0.083 0.128 0.1625 去離子水 至 100.00 至 100.00 至 100.00 至 100.00 至 100.00 至 100.00 酸驗値 5.6 6.2 7.5 8.2 8.9 9.5 表3 產物 酸驗値 平行測定數目 結合平均量微克/公分 1(標準） 7.0 10 0.32 2(標準） 7.0 10 4.67 3(標準） 7.0 8 * 8.18 4(標準） 7.0 10 9.37 — 5(漱口劑） 5.6 10 4.76 6(漱口劑） 6.2 8 6.51 7(漱口劑） 7.5 10 5.66 一 -11 - 本纸張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） (請先閱讀背面之注意事項 r本頁) -裝. 、\'0 線 5 2 3 2 8 A7 B7 發明説明（9 ) 8(漱口'劑） 8.2 10 6.23 9(漱口劑） 8.9 9 6.83 10(漱口劑） 9.5 10 6.25 結果顯示酸鹼値5.6 (漱口劑5 )至酸鹼値6.2 (漱口劑6)時 結合明顯增加。當酸驗値由6.2增加至9.5 (漱口劑6 - 1 0 ) 時，產物間無法觀察到更明顯的差異。 此實驗説明如果使用的漱口劑酸鹼値大於6時能促進結 合。 請 先 閲 讀 背 ιέ 之 /'i* 意 書 χβ： 本 頁 裝 訂 h% 經濟部中央標準局員工消費合作社印製 12- 本紙張尺度適用中國國家標準（CNS ) A4規格（210X 297公釐） 申請曰期 87.1.26 案 號 87101101 類 别 阶h、1 (以上各攔由本局塡註） 修正 本年月R補充 90。3。-5 A4 C4 中文說明書修正頁(％年3月）518232 f|專利説明書 發明 一、新型名稱 中 文 一種具有雙氯苯雙胍己烷和聚乙烯吡咯烷酮之兩相漱 口劑組合物 英 文 TWO PHASE MOUTHWASH COMPOSITION COMPRISING CHLORHEXIDINE AND POLYVINYL pyrrotjdone 姓 名 國 籍 1·史帝芬艾德華亞歷山德 2. 裔斯丁衛斯里 3. 馬克安德瑞威克斯 均英國 ❿ 裝· 發明 創作 人 住、居所 均英國塞瑞郡威布里基市聖喬奇斯道史密斯克林貝克 曼消費者保健中心 訂 姓 名 (名稱） 英商史密斯克林貝克曼公司 線 經濟部智慧財產局員工消費合作社印製 申請人 國 籍 住、居所 (事務所) 代表人 姓 名 英國 英國米德萊赛省班特福市新界 大衛·羅伯茲 本紙張尺度適用中國國家標準（CNS) A4規格（210 X 297公爱jCremophor RH60 0.225 0.225 0.225 0.225 0.225 0.225 Edible oil 0.12 0.12 0.12 0.12 0.12 0.12 Acetic acid 96 6.50 6.50 6.50 6.50 6.50 6.50 Blue dye solution 0.10 0.10 0.10 0.10 0.10 0.10 Glycerin 5.00 5.00 5.00 5.00 5.00 5.00 PVP 5.00 5.00 5.00 5.00 5.00 5.00 Sodium acetate 0.70 0.70 0.70 0.70 0.70 0.70 Sodium fluoride 0.05 0.05 0:05 0.05 0.05 0.05 Sodium benzamidine sodium 0.052 0.052 0.052 0.052 0.052 0.052 0.052 Acetic acid solution 50% w / w 0.625 Pain NaOH solution 10.2% w / w wheel 0.073 0.083 0.128 0.1625 Deionized water to 100.00 to 100.00 to 100.00 to 100.00 to 100.00 to 100.00 Acid test 5.6 6.2 7.5 8.2 8.9 9.5 Table 3 Number of parallel tests of product acid test combined with average amount of micrograms / cm 1 (standard) 7.0 10 0.32 2 (standard ) 7.0 10 4.67 3 (standard) 7.0 8 * 8.18 4 (standard) 7.0 10 9.37 — 5 (gargle) 5.6 10 4.76 6 (gargle) 6.2 8 6.51 7 (gargle) 7.5 10 5.66 a-11 -This paper size is applicable to China National Standard (CNS) A4 (210X 297mm) (Please read the precautions on the back page first)-Installed. \ '0 line 5 2 3 2 8 A7 B7 Description of the invention (9) 8 (mouthwash 'agent) 8.2 10 6.23 9 (mouthwash) 8.9 9 6.83 10 (mouthwash) 9.5 10 6.25 The result shows that pH 5.6 (mouthwash) 5) At pH 6.2 (mouthwash 6), the binding increased significantly. As the acid test increased from 6.2 to 9.5 (mouthwash 6-10), no more noticeable difference was observed between the products. This experiment shows that if the mouthwash pH 値 is greater than 6, the combination can be promoted. Please read the back / 'i * intention letter χβ: This page is bound by h% Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 12- This paper size applies to China National Standard (CNS) A4 (210X 297 mm) Application Date 87.1.26 Case No. 87101101 Category steps h, 1 (The above blocks are annotated by this Bureau) Amend this month R to 90.3. -5 A4 C4 Chinese Manual Correction Page (% March) 518232 f | Patent Specification Invention I. New Name Chinese A Two-Phase Mouthwash Composition with Dichlorophenformin Hexane and Polyvinyl Pyrrolidone English TWO PHASE MOUTHWASH COMPOSITION COMPRISING CHLORHEXIDINE AND POLYVINYL pyrrotjdone Name Nationality 1. Steven Edward Alexandre 2. Steve Wesley 3. Mark Andre Vickers are all outfits in the United Kingdom St. Georges Road, Smithbridge, Beckman Consumer Health Center, County Weybridge, County (Name) British Business Smithsklin Beckman Company Line, Department of Economics, Intellectual Property Bureau, Employee Consumption Cooperative, Printing Applicant Nationality Residence, Domicile (Office) Name of Representative David Roberts, New Territories, Banterford, UK, Middlesex, UK. This paper is sized for the Chinese National Standard (CNS) A4 (210 X 297).